natgillin/translations-raw huggingface dataset:
To ensure correct dosing during the treatment period the owner should seek advice from the responsible veterinarian in connection to each monthly 
Da se zagotovi pravilno odmerjanje zdravila v času zdravljenja naj lastnik poišče nasvet o mesečnem prilagajanju odmerka pri odgovornem veterinarju.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 
V primeru naključnega zaužitja, takoj poiščite zdravniško pomoč in pokažite zdravniku navodilo za uporabo ali ovojnino.
Dirlotapide 5 mg/ml is a colourless to pale yellow solution. 
NAVEDBA ZDRAVILNE UČINKOVINE IN DRUGIH SESTAVIN Dirlotapid 5 mg/ml je brezbarvna do bledo rumena raztopina.
These adjustments should be continued until the weight targeted at the start of therapy is achieved. 
Odmerek zdravila se tako prilagaja dokler se ne doseže na začetku zdravljenja
If vomiting, diarrhoea or significantly reduced appetite or excessive weight loss occurs, treatment should be interrupted and the advice of a veterinarian should be sought. 
Če se pojavi bruhanje, driska, občutno zmanjšanje apetita ali čezmerna izguba telesne mase, se zdravljenje prekine in poišče nasvet veterinarja.
At the end of each month of therapy, the percentage of bodyweight loss should be determined. 
Procent izgubljene telesne mase se določi na koncu vsakega meseca zdravljenja.
Slentrol must not be used during pregnancy and lactation. 
Slentrola se ne sme uporabljati med brejostjo ali v času laktacije.
If vomiting, diarrhoea or significantly reduced appetite or excessive weight loss occurs, treatment should be interrupted. 
Če se pojavi bruhanje, diareja ali občutno zmanjšanje apetita ali prevelika izguba telesne mase, se zdravljenje prekine.
Manufacturer responsible for batch release: 
Izdelovalec, odgovoren za sproščanje serij:
If accidental eye exposure occurs, flush the eyes immediately with clean 
Če pride zdravilo nenamerno v oči, jih takoj sperite s čisto vodo.
Following these initial 4 weeks of therapy, dogs should be weighed monthly during treatment and dose adjustments are made monthly according to effect as described below. 
Po začetnih 4 tednih zdravljenja je potrebno pse med zdravljenjem mesečno tehtati in mesečno prilagajati odmerek glede na učinek, ki je opisan spodaj.
In order to avoid this rebound weight gain, it is necessary to feed the animals to maintenance energy requirements. 
Da se izognete ponovnemu povečanju telesne mase, je potrebno hraniti živali tako, da prejemajo le vzdrževalno količino energije.
Although not observed in clinical trials, in the case where bodyweight loss since previous monthly weighing has been 12% per month (equivalent to 0.4% bodyweight per day), the dose should be reduced by 25%. 
Čeprav v kliničnih poskusih ni bilo opaženo, se v primerih zmanjšanja telesne mase glede na prejšnji mesec za ≥12 % na mesec (enako 0,4 % telesne mase na dan), priporoča zmanjšanje odmerka za 25 %.
Detailed information on this product is available on the website of the European Medicines Agency 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu/.
In case of excessive weight loss greater than 12% per month, the dose volume of the veterinary medicinal product should be reduced (by 25%). 
Izboljšanje stranskih učinkov se bo pojavilo hitro po prenehanju zdravljenja.V primeru izgube telesne mase več kot 12 % na mesec je treba količino zdravila zmanjšati (za 25 %).
If your dog suffers from repeated vomiting, diarrhoea or significantly reduced appetite and excessive weight loss, you should consult your veterinary surgeon who may 
Če vaš pes trpi zaradi ponavljajočega bruhanja, diareje ali ima občutno zmanjšan apetit in je izgubil pretirano veliko telesne mase, se posvetujte z veterinarjem, ki bo morda svetoval prekinitev zdravljenja.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE
Slentrol may cause eye-irritation. 
Slentrol lahko draži oči.
Do not use in dogs with impaired liver function. 
Ne uporabite zdravila pri psih z okvarjenim delovanjem jeter.
Resolution of adverse reactions will occur shortly after suspension of treatment. 
Vsi neželeni učinki bodo prenehali v kratkem času po prekinitvi zdravljenja.
In case of contact with the skin, wash off any veterinary medicinal product immediately with soap and 
V primeru kontakta s kožo, zdravilo za uporabo v veterinarski medicini takoj sperite z milom in vodo.
The recommended starting dose is 0.05 mg/kg initial bodyweight per day (0.01 ml/kg/day). 
Priporočen začetni odmerek zdravila je 0,05 mg/kg začetne telesne mase na dan (0,01ml/kg/dan).
Dogs should undergo a physical examination by a veterinarian before commencing treatment, and a desired bodyweight or body condition score identified. 
Pred začetkom zdravljenja mora pse pregledati veterinar in zabeležiti želeno ciljno maso ali telesno kondicijo.
In clinical trials, treated animals rapidly regained weight following cessation of treatment when diet was not restricted. 
V kliničnih poskusih so zdravljene živali po prenehanju zdravljenja hitro spet pridobile izgubljeno maso, če prehrana ni bila omejena.
The recommended starting dose of Slentrol is 0.05 mg/kg (0.01ml/kg) by oral administration. 
Priporočen začetni odmerek zdravila Slentrol je 0,05mg/kg (0,01 ml/kg) za peroralno dajanje.
In clinical studies, vomiting, sometimes accompanied by signs of lethargy, anorexia or diarrhoea was observed during treatment with the veterinary medicinal product. 
V kliničnih raziskavah se je pri zdravljenju pojavilo bruhanje, ki so ga občasno spremljali zaspanost, anoreksija ali driska.
Do not use in dogs in the growth phase. 
Ne uporabite zdravila pri psih v rasti.
Sporadic and mild ALT (alanine aminotransferase) elevations up to 4 times the upper reference range and not associated with histopathological liver lesions or noticeable changes in other liver parameters may be observed in some dogs during the course of treatment. 
Pri nekaterih psih se lahko med zdravljenjem opazi sporadično in blago zvišanje vrednosti ALT (alanin aminotransferaze) do 4-kratne referenčne vrednosti, ki pa ni povezano s histopatološkimi spremembami v jetrih ali drugimi opaznimi spremembami v vrednosti jetrnih parametrov.
Slovenská republika Zoetis Luxembourg Holding Sarl, o.z. 
Česká republika Zoetis Česká republika, s.r.o.
In clinical trials, treated dogs rapidly regained weight following cessation of treatment when diet was not restricted. 
V kliničnih poskusih so zdravljeni psi po prenehanju zdravljenja hitro spet pridobili izgubljeno maso, če prehrana ni bila omejena.
Therefore, for dogs receiving treatments in addition to the veterinary medicinal product, drug interactions should be 
Zato je treba pri psih, hkrati zdravljenimi z drugimi zdravili, natančno opazovati njihovo medsebojno delovanje.
Bottles of 50 ml are packed with two dosing devices of 3 ml. 
50 ml stekleničke so v paketu z dvema napravama za odmerjanje 3 ml.
Thus, during treatment or at the end of treatment at the latest, an appropriate feeding and exercise regimen should be implemented in order to ensure long term maintenance of the bodyweight. 
Med zdravljenjem ali ob koncu le-te je potrebno določiti pravilen način prehrane in gibanja, da se zagotovi dolgoročno ohranjanje telesne
Bottles of 150 ml are packed with two dosing devices of 10 ml. 
150 ml stekleničke so v paketu z dvema napravama za odmerjanje 10 ml.
Any clinical suspicion of liver disease or dysfunction during treatment should be investigated through the evaluation of liver function. 
Vsak sum na jetrno obolenje ali njihovo zmanjšano delovanje je treba preučiti z oceno jetrnih funkcij.
In order to avoid this rebound weight gain, it is necessary to feed the dogs to maintenance energy requirements. 
Da se izognete ponovnemu povečanju telesne mase, je potrebno hrani živali tako, da se vzdržujejo enegetske potrebe.
Administer the veterinary medicinal product once daily directly into the mouth or on a small amount of food. 
Zdravilo dajte psu direktno v gobec ali naj ga zaužije z manjšo količino hrane.
Dogs should undergo a physical examination before commencing treatment, and a desired bodyweight or a body condition score identified. 
Pred začetkom zdravljenja opravite klinični pregled psa in določite želeno ciljno maso ali telesno kondicijo.
In order to avoid this rebound weight gain, it is necessary during treatment or at the end of treatment at the latest, to establish the appropriate level of food intake and physical activity needed to ensure long term maintenance of the bodyweight. 
Da se izognete ponovnemu povečanju telesne mase, je treba hraniti živali tako, da se pravilen način prehrane in gibanja vzpostavi že med zdravljenjem ali proti koncu zdravljenja, da se zagotovi dolgoročno vzdrževanje telesne mase.
Dosing may be recommenced at the same or at a reduced dose volume (reduced by 25%), but if vomiting reoccurs, the veterinary medicinal product may 
Ponovno odmerjanje naj bo v enaki ali zmanjšani količini (zmanjšani za 25 %).
Polypropylene bottles of 20, 50 and 150 ml fitted with a low density polyethylene (LDPE) Press-In-bottle adapter and a child resistant closure. 
Polietilenske plastenke po 20, 50 in 150 ml, zaščitene s pokrovčkom na pritisk iz polietilena nizke 20 ml stekleničke so v paketu z dvema napravama za odmerjanje 1 ml.
If the bodyweight loss since previous monthly weighing has been 3% bodyweight per month (equivalent to 0.1% bodyweight per day); the dose (number of ml administered) should be kept the same. 
Če je bila izguba telesne mase v primerjavi s prejšnjim mesecem ≥3 % telesne mase na mesec (enako 0,1 % telesne mase na dan), se obdrži enak odmerek zdravila.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA Imetnik dovoljenja za promet z zdravilom
Do not use in dogs during pregnancy and lactation. 
Ne uporabite pri psicah v obdobju brejosti in laktacije.
Any indication of progressive liver damage or of dysfunction should result in discontinuation of treatment. 
Ob vsakem znaku napredujoče poškodbe jeter ali njihovega zmanjšanega delovanja, je treba zdravljenje prekiniti, saj je zdravilo kontraindicirano.
When the veterinary medicinal product is drawn into syringe, administer immediately. 
Ko je zdravilo v brizgi, ga porabite takoj.
PHARMACOLOGICAL PROPERTIES 
Zdravilo Slentrol se
MTP (Microsomal Trigylyceride transfer Protein) inhibitors as a class have the potential to disrupt yolk sac development and laboratory studies on rats and rabbits have shown evidence of embryolethality, teratogenicity, and developmental toxicity. 
Laboratorijske preiskave na podganah in kuncih so dokazale embrioletalnost, teratogenost in razvojno toksičnost.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE
Thus, during treatment or at the end of treatment at the latest, an appropriate feeding and exercise regimen should be implemented in order to ensure long term 
Pravilen način prehrane in gibanja se vzpostavi že med zdravljenjem ali proti koncu zdravljenja, da se zagotovi dolgoročno vzdrževanje
5.1 Pharmacodynamic properties 
4.11 Karenca
Suomi/Finland Zoetis Finland Oy Puh/Tel: +358 (0)9 4300 40 
United Kingdom Zoetis UK Limited Tel: +44 (0) 845 300 8034
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE 
B POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE
4.2 Indications for use, specifying the target species 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Kot dodatek pri nadziranju prekomerne telesne mase in debelosti pri odraslih psih.
Dogs with evidence of liver dysfunction should not be treated with the veterinary medicinal product. 
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.
The liver function of dogs suspected of suffering from a liver disease or dysfunction should be evaluated, before commencing treatment with the veterinary medicinal product. 
Pred uporabo zdravila za uporabo v veterinarski medicini morate oceniti delovanje jeter pri psih,, za katere se sumi, da so podvrženi kateremukoli jetrnemu obolenju ali zmanjšanemu delovanju jeter.
Ìsland 
KARENCA
MTP inhibitors (microsomal trigylyceride transfer protein inhibitors) as a class have the potential to disrupt yolk sac development and laboratory studies on rats and rabbits have shown evidence of embryolethality, teratogenicity, and developmental 
Zdravila iz skupine zaviralcev MTP (zaviralci mikrosomalnih proteinov za prenos trigliceridov) lahko povzročijo motnje v razvoju rumenjakove vrečke.
Fertility studies have not been conducted in the target species - use in dogs intended for breeding should be subject to a risk-benefit analysis by your veterinarian. 
Raziskav plodnosti niso izvajali na ciljni živalski vrsti.
The liver function of dogs suspected of suffering from a liver disease or dysfunction should be evaluated before commencing treatment with the veterinary medicinal product. 
Pred uporabo zdravila za uporabo v veterinarski medicini morate oceniti delovanje jeter pri psih, za katere se sumi, da so podvrženi kateremukoli jetrnemu obolenju ali zmanjšanemu delovanju jeter.
6 (conditional) 
6.2 Inkompatibilnosti
Zoetis Ireland Limited Tel: +353 (0) 1 467 6650 
Magyarország Zoetis Hungary Kft. Tel: +361 488 3695
These measures should 
Če opazite te
Icepharma hf. 
Brejost in laktacija:
5 (conditional) 
POSEBNO(A) OPOZORILO(A)
Do not use during pregnancy or lactation. 
Ne uporabite zdravila pri psicah v obdobju brejosti ali laktacije.
To be supplied only on veterinary prescription. 
Če se bruhanje ponovi, se zdravilo za uporabo v veterinarski medicini preneha uporabljati.
Actira was initially approved in June 1999. 
Zdravilo Actira je bilo prvič odobreno junija 1999.
QUÍMICA FARMACEUTICA BAYER, S. L. 
FARMACEUTICA BAYER, S. L.
- The Committee considered the Referral made under Article 6(12) of Commission Regulation (EC) No 1084/2003, for Actira and associated names (See Annex 1). 
- Odbor je preučil napotitev, pripravljeno v skladu s členom 6(12) Uredbe Komisije (ES) št. 1084/2003, za zdravilo Actira in z njim povezana imena (glejte Dodatek I).
This procedure is a referral following a Mutual Recognition Procedure concerning the above variation application which was submitted for Actira film-coated tablets to Germany as Reference Member State (RMS) and the Concerned Member States (CMS) AT, BE, DK, EL, ES, FI, IT, LU, PT and SE on 5 December 2006. 
Ta postopek je napotitev na podlagi postopka medsebojnega priznavanja v zvezi z zgornjo vlogo za spremembo, ki je bila za zdravilo Actira - filmsko obložene tablete Nemčiji kot referenčni državi članici in zadevnim državam članicam AT, BE, DK, EL, ES, FI, IT, LU, PT in SE predložena dne 5. decembra 2006.
The MRP variation application DE/H/158/01/II/32 concerned an extension of the indication to include the treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis. 
Vloga za odobritev spremembe po postopku medsebojnega priznavanja DE/H/158/01/II/32 je zadevala razširitev indikacije, tako da bi vključevala zdravljenje blagih do zmernih pelvičnih vnetnih bolezni tj. okužb zgornjega genitalnega trakta, vključno s salpingitisom in endometritisom.
Actira film-coated tablets contain 400 mg moxifloxacin as hydrochloride. 
Actira - filmsko obložene tablete vsebujejo 400 mg moksifloksacina v obliki klorida.
Objections and concerns over the efficacy and safety of Actira in the proposed indication were raised during the Mutual Recognition variation procedure. 
Med postopkom medsebojnega priznavanja za prijavljeno spremembo so bili izraženi ugovori in pomisleki glede učinkovitosti in varnosti zdravila Actira pri predlagani indikaciji.
- The Committee considered that robust data is available showing the efficacy of Actira in the indication “Treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis” , however due to emerging resistance of N. gonorrhoeae, moxifloxacin should not be used in empirical monotherapy, unless moxifloxacinresistant N. gonorrhoeae can be excluded. 
- Odbor je sklenil, da so na voljo trdni podatki, ki dokazujejo učinkovitost zdravila Actira pri indikaciji „zdravljenje blagih do zmernih pelvičnih vnetnih bolezni, tj. okužb zgornjega genitalnega trakta, vključno s salpingitisom in endometritisom“, vendar pa se moksifloksacin zaradi pojava odpornosti na N. gonorrhoeae ne sme uporabljati v empirični monoterapiji, razen če je mogoče izključiti N. gonorrhoeae, odporno na moksifloksacin.
- The Committee, in view of the presented data on efficacy and safety, considered that the Benefit / Risk balance for Actira and associated names in the “ The treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis” with the restrictions concerning empirical monotherapy was favourable; - The CHMP, as a consequence, recommended the amendment of the Summary of Product Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Actira and associated names (see Annex I). 
- Odbor je ob upoštevanju predloženih podatkov o učinkovitosti in varnosti menil, da je razmerje med koristmi in tveganji za zdravilo Actira in z njim povezana imena pri „zdravljenju blagih do zmernih pelvičnih vnetnih bolezni, tj. okužb zgornjega genitalnega trakta, vključno s salpingitisom in endometritisom“, upoštevaje omejitve glede empirične monoterapije, ugodno.
Plasma 
QUÍMICA
BE - Belgium Bayer AG 51368 Leverkusen Germany 
PT - Portugalska Bayer AG 51368 Leverkusen Nemčija
Intravenous use Vial (glass) 
Intravenska uporaba viala (steklo)
Dogs were followed for 18 weeks after treatment. 
Pse so spremljali 18 tednov po zdravljenju.
Area vascularity should be maintained. 
Ohraniti je treba vaskularizacijo območja.
Each kit contains: 
Vsak komplet vsebuje:
Do not use more than 3.2 ml. 
Ne uporabite več kot 3,2 ml.
1 Burtt Road Andover MA 01810 USA 
1 Burtt Road Andover MA 01810 ZDA
For reconstitution. 
Za rekonstitucijo.
Do not store above 25 C. Do not refrigerate. 
Ne shranjujte pri temperaturi nad 25 C. Ne shranjujte v hladilniku.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu
It must not be re-sterilised. 
Ni ga dovoljeno ponovno strerilizirati.
Instructions for preparation and use 
Navodila za pripravo in uporabo
C. Implantation 
C. Implantacija
Summary of the cumulative percent of fracture unions by week and treatment Weeks 
Povzetek kumulativnega odstotka zacelitve kosti glede na teden in način zdravljenja Tedni
Treatment TruScient + SOC (n=84) SOC (n=42) SOC = standard of care 
Zdravljenje TruScient + SOC (n=84) SOC (n=42) SOC = standardni postopki oskrbe
BMP-2 plays a critical role during foetal development. 
BMP-2 ima pomembno vlogo v času razvoja ploda.
B. Prepare TruScient sponges in the sterile field: 
B. Priprava gobic s TruScient v sterilnem območju:
TruScient is intended for single use only. 
TruScient je namenjen samo za enkratno uporabo.
Figure 2: Preparation of TruScient sponges 
Slika 2: Priprava gobic s TruScient
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinarian surgeon. 
Če opazite kakršne koli resne stranske učinke ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite svojega veterinarja.
Development of BMP-2 antibodies occurred in 6.9% of dogs receiving TruScient vs. 4.3% of dogs in the control group. 
Do nastanka protiteles proti BMP-2 je prišlo pri 6,9 % psov, ki so prejeli TruScient in 4,3 % psov v kontrolni skupini.
Follow the instructions for preparation below. 
Za pripravo upoštevajte spodnja navodila.
Dry the fracture site to the extent possible. 
Mesto zloma osušite do največje možne mere.
Radiographic, biomechanical, and histological evaluation of the induced bone indicates that it functions biologically and biomechanically as native bone. 
Radiografski, biomehanski in histološki testi induciranega kostnega tkiva kažejo, da to tako biološko kot biomehansko deluje kot nativna kost.
The recommended dose is up to two sponges (2.5 x 5 cm) per dog. 
Priporočeni odmerek je do dve gobici (2,5 x 5 cm) za psa.
4.4 Special warnings for each target species 
4.4 Posebna opozorila za vsako ciljno živalsko vrsto Jih ni
Sponge for TruScient 
Goba za TruScient
Solvent: Water for injections 
Vehikel: Voda za injekcije
Pharmacotherapeutic group: Bone Morphogenetic Proteins ATCvet code: QM05BC01 
FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: Proteini za morfogenezo kosti, oznaka ATC vet: QM05BC01
TruScient can cause initial resorption of surrounding trabecular bone. 
TruScient lahko povzroči začetno resorpcijo okolne trabekularne kostnine.
*Dibotermin alfa (recombinant human Bone Morphogenetic Protein-2; rhBMP-2) is a human protein derived from a recombinant Chinese Hamster Ovary (CHO) cell line. 
*Dibotermin alfa (rekombinantni humani protein za morfogenezo kosti-2; rhBMP-2) je človeški protein, pridobljen iz rekombinantne vrste ovarijskih celic kitajskega hrčka (CHO - Chinese Hamster Ovary).
Do not use in dogs that are skeletally immature, have an active infection at the operative site, pathological fracture, or any active malignancy. 
Ne uporabite pri psih z nezrelim okostjem, aktivno okužbo v operativnem območju, patološkim zlomom ali katerimkoli malignim obolenjem.
EXP {month/year} Shelf life in the vial after reconstitution: 3 hours 
EXP {mesec/leto} Rok uporabnosti po rekonstituciji: 3 ure
Clinical pharmacology studies demonstrate that the absorbable collagen sponge alone is not osteoinductive and is completely resorbed over time. 
Klinične farmakološke študije kažejo, da sama kolagenska goba ni osteoinduktivna in se s časom popolnoma resorbira.
Glutamic acid 
Glutaminska kislina
The influence of anti-BMP-2 antibody formation on foetal development has not been assessed. 
Vpliva nastanka anti-BMP-2 protiteles na razvoj ploda niso preučili.
Wait a MINIMUM of 15 minutes before using the prepared sponges. 
Počakajte NAJMANJ 15 minut, preden uporabite pripravljeni gobici.
It is concluded therefore that at the site of implantation dibotermin alfa is slowly released from the matrix and rapidly cleared when taken up into the systemic circulation. 
Sklepamo lahko torej, da se na mestu implantacije dibotermin alfa iz matriksa sprošča počasi, medtem ko je njegovo odstranjevanje iz sistemske cirkulacije hitro.
Therefore, in the absence of clinical data, the veterinary medicinal product should not be used for direct applications to trabecular bone when transient bone resorption may create a risk of bone fragility and, thus, increase the risk of implant failure. 
Ker ni na voljo kliničnih podatkov, se tega zdravila za uporabo v veterinarski medicini ne sme neposredno dajati na trabekularno kost v primerih, ko bi prehodna resorpcija kostnine lahko povzročila tveganje za lomljivost kosti in tako ogrozila uspešnost implantacije.
The antibody titers did not correlate with any adverse clinical sign including any immune mediated adverse events such as allergic reactions. 
Titer protiteles ni bil v korelaciji s katerimkoli neželenim kliničnim znakom, vključno z imunsko pogojenimi neželenimi učinki kot so alergijske reakcije.